Candesartan cilexetil in the treatment of chronic heart failure

References

• LevyDKenchaiahSLarsonMGLong-term trends in the incidence of and survival with heart failureN Engl J Med2002347139740212409541
   PubMed Web of Science ®Google Scholar
• StewartSMacIntyreKCapewellSHeart failure and the aging population: an increasing burden in the 21st centuryHeart200389495312482791
   PubMed Web of Science ®Google Scholar
• RedfieldMMHeart failure – an epidemic of uncertain proportionsN Engl J Med20023471442144412409548
   PubMed Web of Science ®Google Scholar
• European Study Group on Diastolic Heart FailureHow to diagnose diastolic heart failureEur Heart J19981999010039717033
   PubMed Web of Science ®Google Scholar
• JessupMBrozenaSHeart failureN Engl J Med20033482007201812748317
   PubMed Web of Science ®Google Scholar
• DicksteinKCohen-SolalAFilippatosGESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of CardiologyDeveloped in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)Eur Heart J2008292388244218799522
   PubMedGoogle Scholar
• PackerMFowlerMBRoeckerEBCarvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study GroupEffect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) studyCirculation20021062194219912390947
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators and CommitteesThe Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialLancet199935391310023943
   PubMed Web of Science ®Google Scholar
• MERIT-HF Study GroupEffect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)Lancet19993532001200710376614
   PubMed Web of Science ®Google Scholar
• The CONSENSUS Trial Study GroupEffects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)N Engl J Med1987316142914352883575
   PubMed Web of Science ®Google Scholar
• The SOLVD InvestigatorsEffect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failureN Engl J Med19913252933022057034
   PubMed Web of Science ®Google Scholar
• GargRYusufSOverview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor TrialsJAMA1995273145014567654275
   PubMed Web of Science ®Google Scholar
• PittBZannadFRemmeWJRandomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failureN Engl J Med199934170971710471456
   PubMed Web of Science ®Google Scholar
• PittBRemmeWZannadFEplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionN Engl J Med20033481309132112668699
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRCollaborative Study GroupRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med200134585186011565517
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDRENAAL Study InvestigatorsEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med200134586186911565518
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRBKjeldsenSELIFE Study GroupCardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogISCOPE Study GroupThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens20032187588612714861
   PubMed Web of Science ®Google Scholar
• PittBSegalRMartinezFARandomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)Lancet19973497477529074572
   PubMed Web of Science ®Google Scholar
• PittBPoole-WilsonPASegalREffect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE IILancet20003551582158710821361
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGValsartan Heart Failure Trial InvestigatorsA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med20013451667167511759645
   PubMed Web of Science ®Google Scholar
• PfefferMABraunwaldEMoyéLAEffect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE InvestigatorsN Engl J Med19923276696771386652
   PubMed Web of Science ®Google Scholar
• SwedbergKHeldPKjekshusJEffects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)N Engl J Med19923276786841495520
   PubMed Web of Science ®Google Scholar
• FlatherMDYusufSKøberLLong-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative GroupLancet20003551575158110821360
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med20033491893190614610160
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKCHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet200336277778113678871
   PubMed Web of Science ®Google Scholar
• MassieBMCarsonPEMcMurrayJJThe I-PRESERVE Investigators. 2008 Irbesartan in Patients with Heart Failure and Preserved Ejection FractionN Engl J Med20083592456246719001508
   PubMed Web of Science ®Google Scholar
• NishikawaKNakaTChataniFCandesartan cilexetil: a review of its preclinical pharmacologyJ Hum Hypertens199711Suppl 2S9S179330999
   PubMed Web of Science ®Google Scholar
• MeredithPACandesartan cilexetil – a review of effects on cardiovascular complications in hypertension and chronic heart failureCurr Med Res Opin2007231693170517588300
   PubMed Web of Science ®Google Scholar
• SakataYYamamotoKManoTAngiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca(2+) regulatory proteins and extracellular matrixJ Hypertens2003211737174512923407
   PubMed Web of Science ®Google Scholar
• McKelvieRSYusufSPericakDComparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study InvestigatorsCirculation19991001056106410477530
   PubMed Web of Science ®Google Scholar
• McKelvieRSRouleauJLWhiteMComparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failureEur Heart J2003241727173414522567
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKCHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet200336276777113678869
   PubMed Web of Science ®Google Scholar
• WhiteMLepageSLavoieJEffects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failureJ Card Fail200713869417395047
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSCHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet200336277277613678870
   PubMed Web of Science ®Google Scholar
• YoungJBDunlapMEPfefferMACandesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trialsCirculation20041102618262615492298
   PubMed Web of Science ®Google Scholar
• DagenaisGRPogueJFoxKAngiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trialsLancet200636858158816905022
   PubMed Web of Science ®Google Scholar
• DemersCMcMurrayJJSwedbergKCHARM Investigators. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failureJAMA20052941794179816219883
   PubMed Web of Science ®Google Scholar
• MaggioniAPLatiniRCarsonPEVal-HeFT InvestigatorsValsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)Am Heart J200514954855715864246
   PubMed Web of Science ®Google Scholar
• DucharmeASwedbergKPfefferMACHARM InvestigatorsPrevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programAm Heart J2006152869216838426
   PubMed Web of Science ®Google Scholar
• PoornimaIGParikhPShannonRPDiabetic cardiomyopathy: the search for a unifying hypothesisCirc Res20069859660516543510
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMVALUE trial groupOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet20043632022203115207952
   PubMed Web of Science ®Google Scholar
• AbuissaHJonesPGMarsoSPAngiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trialsJ Am Coll Cardiol20054682182616139131
   PubMed Web of Science ®Google Scholar
• AndrawsRBrownDLEffect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials)Am J Cardiol2007991006101217398202
   PubMed Web of Science ®Google Scholar
• YusufSOstergrenJBGersteinHCCandesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program InvestigatorsEffects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failureCirculation2005112485315983242
   PubMed Web of Science ®Google Scholar
• AnandISLatiniRFloreaVGVal-HeFT InvestigatorsC-reactive protein in heart failure: prognostic value and the effect of valsartanCirculation20051121428143416129801
   PubMed Web of Science ®Google Scholar
• O’MearaESolomonSMcMurrayJEffect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeEur Heart J2004251920192615522471
   PubMed Web of Science ®Google Scholar
• DesaiASSwedbergKMcMurrayJJCHARM Program InvestigatorsIncidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM ProgramJ Am Coll Cardiol2007501959196617996561
   PubMed Web of Science ®Google Scholar
• WeirRAMcMurrayJJPuuMCHARM InvestigatorsEfficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blockerFindings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialEur J Heart Fail20081015716318242128
   PubMed Web of Science ®Google Scholar
• Cohen-SolalAMcMurrayJJSwedbergKFor the CHARM InvestigatorsBenefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity programmeEur Heart J2008293022302818987098
   PubMed Web of Science ®Google Scholar